BioSpace News Archive

Samsung Biologics, the world’s leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal 2021.

LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended March 31, 2021.

Exact Sciences announces study results published in Mayo Clinic Proceedings showing that Cologuard is the most cost-effective colorectal cancer screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test, for a wide range of adherence scenarios.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting

- This flagship facility in the principality, the Pyrenees Immunology Research Center (PYIRC), will be one of the few immunology-dedicated research centers in Europe and will serve as an international reference center for the development of treatments for immune system disorders through translational and clinical expertise

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021 , after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company’s performance and answer questions.

Global Blood Therapeutics, Inc. announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after U.S. financial markets close.

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a data update, announced Phase 1b/2 program priorities across seven hematologic and solid tumor indications, and reported governance changes with its Board of Directors.

The global regulatory affairs outsourcing market is fragmented and a very small number of players have been able to acquire dominance in the market.